Epizyme, Inc. (NASDAQ:EPZM) headquartered in Cambridge, will host a conference call for the investment community to discuss the 2Q20 earnings result on 4th August 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.epizyme.com
Earnings Expectation
Epizyme, Inc. is set to announce second quarter earning results on Tuesday 4th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, EPZM to report 2Q20 loss of $ 0.61 per share. For the full year, analysts anticipate top line of $ 29.95 million, while looking forward to loss of $ 2.39 per share bottom line.
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The companys lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer.
